Search

Your search keyword '"Ndrepepa, Gjin"' showing total 10 results
Start Over Author "Ndrepepa, Gjin" Publication Year Range This year
10 results on '"Ndrepepa, Gjin"'

1. Incidence and pattern of urgent revascularization in acute coronary syndromes treated with ticagrelor or prasugrel

Author

Aytekin, Alp, Scalamogna, Maria, Coughlan, J. J., Lahu, Shqipdona, Ndrepepa, Gjin, Menichelli, Maurizio, Mayer, Katharina, Wöhrle, Jochen, Bernlochner, Isabell, Witzenbichler, Bernhard, Hochholzer, Willibald, Sibbing, Dirk, Angiolillo, Dominick J., Hemetsberger, Rayyan, Tölg, Ralph, Valina, Christian, Müller, Arne, Kufner, Sebastian, Liebetrau, Christoph, Xhepa, Erion, Hapfelmeier, Alexander, Sager, Hendrik B., Joner, Michael, Richardt, Gert, Laugwitz, Karl-Ludwig, Neumann, Franz Josef, Schunkert, Heribert, Schüpke, Stefanie, Kastrati, Adnan, and Cassese, Salvatore

Published
2024
Full Text
View/download PDF

8. Coronary no-reflow and adverse events in patients with acute myocardial infarction after percutaneous coronary intervention with current drug-eluting stents and third-generation P2Y12 inhibitors.

Author

Ndrepepa, Gjin, Cassese, Salvatore, Xhepa, Erion, Joner, Michael, Sager, Hendrik B., Kufner, Sebastian, Laugwitz, Karl-Ludwig, Schunkert, Heribert, and Kastrati, Adnan

Abstract

Background: The frequency and prognostic value of coronary no-reflow (CNR) was investigated in studies that have used an outdated reperfusion therapy in terms of stent technology and antithrombotic drugs. We assessed the association of CNR with adverse outcomes in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES) and newer antithrombotic drugs, ticagrelor or prasugrel. Methods: This study included 3100 patients with AMI who underwent PCI with current DES and third-generation P2Y12 inhibitors. CNR was defined as Thrombolysis in Myocardial Infarction (TIMI) blood flow grade ≤ 2 at the end of PCI. The primary end point was 1-year incidence of net adverse clinical and cerebral events—a composite end point of death of any cause, myocardial infarction, stroke or major bleeding. Results: CNR was diagnosed in 130 patients (4.2%). The primary end point occurred in 28 patients in the CNR group and 354 patients in the reflow group (cumulative incidence 23.2% and 12.8%; adjusted hazard ratio = 1.53, 95% confidence interval 1.01–2.33; P = 0.049). The 1-year incidences of death or myocardial infarction (14.6% vs. 7.6%; P = 0.003), myocardial infarction (8.8% vs. 3.9%; P = 0.007) and major bleeding (10.9% vs. 5.6%; P = 0.008) were significantly higher in patients with CNR than patients with reflow. The risk of adverse events in patients with CNR was highest within the first 30 days after PCI. Conclusion: In patients with AMI undergoing PCI with current DES and third generation P2Y12 receptor inhibitors, CNR was associated with a higher risk of adverse outcomes at 1 year. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results